TURINGBIO

What TURINGBIO does

TURINGBIO Inc. is a South Korea-based medical AI company founded in 2020, headquartered in Pangyo, Seongnam. It develops evidence-based, multimodal AI-driven diagnostics and digital therapeutics with a primary focus on mental health (depression and generalized anxiety disorder) and an adjacent bioinformatics practice in computational proteomics. The company's product portfolio centers on two consumer/institutional digital therapeutics — DepRx, a Software as Medical Device (SaMD) prescription digital therapeutic delivering 8–12 week Behavioral Activation (BA) treatment via smartphone app — and WeeDool, an AI-powered mental health management platform sold to institutions (companies, universities, public organizations) with administrator reporting. Supporting offerings include WeeDool EAP (Employee Assistance Program), computational proteomics services for biomarker and drug-target identification, and a Multimodal Gen-AI capability combining text, image, and structured data for diagnostic enhancement.

The underlying technology stack combines transformer-based generative AI (GPT, GANs, VAEs, reinforcement learning), deep neural networks for mass spectrometry-based proteomics and DIA (Data Independent Acquisition) workflows, and an AI chatbot for depression diagnosis that has been granted Korean patent protection. Clinical methodology rests on a proprietary MPFEEC-BA framework (six behavioral activation classes — Moderation, Practice, Food, Exercise, Emotion, Cognition — with 250 structured action items) derived from 30+ years of clinical experience and Alfred Adler's Individual Psychology theory. TURINGBIO holds K-FDA IND approval for DepRx (May 2025) and GMP certification for SaMD manufacturing (2024), positioning it among a small set of Korean firms cleared for clinical trials of prescription digital therapeutics.

Revenue mechanics are subscription-based across both products. WeeDool generates institutional subscription revenue via enterprise field sales targeting HR, university administration, and public-sector buyers; DepRx is positioned for direct-to-consumer smartphone distribution with subscription pricing in the non-covered healthcare market following confirmatory clinical trials (expected post-2025). Pricing is not publicly disclosed and the company runs a hybrid go-to-market combining enterprise B2B sales (WeeDool) with self-serve/PLG mobile distribution (DepRx). Strategic partnerships executed in February 2025 with Johns Hopkins University, the University of Georgia's CACHE Center, and the Sangmu Army Artillery School anchor the company's research, US-market, and government/military expansion vectors.

Name

TURINGBIO

Legal name

TURINGBIO Inc.

Website

https://turingbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Short description

TURINGBIO is a South Korean medical AI company developing AI-powered digital therapeutics for mental health and bioinformatics services. Its core offerings are DepRx, a K-FDA-cleared depression digital therapeutic, and WeeDool, an institutional mental health management platform for companies, universities, and public organizations.

Ownership category

akta.pro rank

Product category

Digital Mental Health Therapeutics

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• Digital therapeutics
• Mental health software
• AI bioinformatics
• Behavioral activation therapy
• Medical AI platform

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. DepRx Digital Therapeutics: Software as Medical Device (SaMD) for depression treatment delivered via smartphone app for 8-12 weeks using behavioral activation techniques. Expected to enter non-covered healthcare market after confirmatory clinical trials.
2. WeeDool Institutional Platform: AI-based mental health management program for institutions (companies, universities, public organizations) with administrator reports and personalized management using AI and survey data.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

TURINGBIO develops and sells AI-powered digital therapeutics and bioinformatics software for mental healthcare. Its core products are DepRx, a Software as Medical Device (SaMD) smartphone application delivering 8-12 week Behavioral Activation treatment for depression and anxiety, and WeeDool, an institutional AI-based mental health management platform with administrator reporting for enterprises, universities, and public organizations. Supporting offerings include Multimodal Gen-AI diagnostics and computational proteomics/bioinformatics services.

Product overview

TURINGBIO is a medical AI company offering a platform-plus-products architecture focused on digital healthcare for mental health. The core portfolio includes DepRx (a prescription digital therapeutic for depression), WeeDool (AI mental health management platform for institutions), and WeeDool EAP (employee assistance program). Supporting services include Behavioral Activation treatment protocols, Multimodal Gen-AI technology, Digital Therapeutics development, and Bioinformatics analysis. DepRx and WeeDool operate as distinct product lines addressing consumer/patient and enterprise/institutional markets respectively.

Differentiator

Problem solved

Functional benefit

Brands

• DepRx: Digital therapeutics solution for depression treatment
• WeeDool
• WeeDool EAP

Products and services

• DepRx DepRx (Depression Prescription) is a Software as Medical Device (SaMD) digital therapeutics product for depression and generalized anxiety disorder. It provides personalized 8-12 week treatment via smartphone app using Behavioral Activation (BA) techniques, with daily/weekly effectiveness monitoring using BDI, HAMD, and BADS questionnaires. Targeted at individual patients.
• WeeDool WeeDool is an AI-based digital program for institutional mental health management using Behavioral Activation principles. It systematically measures mental and emotional health of organization members (companies, universities, public organizations) and promotes self-care through personalized management and administrator reporting.
• WeeDool EAP Employee Assistance Program (EAP) powered by WeeDool for organizational mental health support and employee wellness programs, targeted at enterprises and public institutions.
• Behavioral Activation (BA) Treatment Evidence-based therapeutic approach for depression, anxiety, and PTSD delivered as a service. Structured BA (MPFEEC) comprises 250 action items across 6 classes targeting head, heart, stomach, and lower body muscles.
• Bioinformatics Analysis Computational proteomics analysis using AI and machine learning for protein identification, quantification, drug-target interaction (DTI), and biomarker discovery for disease treatment development, leveraging DIA proteomics with deep neural network algorithms.

Quantifiable outcome

• BA found to be equally effective as antidepressant medication and slightly superior to CBT in treating depression
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Johns Hopkins University (JHU) - Department of Biomedical EngineeringcoreStrategic or Co-development Partner · 1 February 2025TuringBio signed a business agreement with JHU's Department of Biomedical Engineering for joint research in mental health. The partnership combines TuringBio's medical AI technology with JHU's neuroscience and biotechnology research capabilities to jointly develop early diagnosis and customized treatment for mental health disorders.
• CACHE (Center for Advanced Human-Computer Ecosystem) at University of GeorgiacoreStrategic or Co-development Partner · 1 February 2025Partnership to develop mental health, rehabilitation, and occupational therapy solutions combining AR, MR, and XR (extended reality) technologies with medical AI. Plans to expand application to global market centered on the United States.
• Sangmu Army Artillery SchoolminorStrategic or Co-development Partner · 1 February 2025MOU to strengthen mental health support for military personnel at the Army Artillery School located in Jangseong-gun, Jeollanam-do.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Headspace Health: Large-scale mental wellness platform combining meditation, coaching and therapy (via Ginger acquisition). Broad incumbent in the same consumer and employer mental health category as TuringBio's WeeDool, with vastly greater distribution and brand.
• BetterHelp (Teladoc Health): Largest direct-to-consumer online therapy marketplace, owned by Teladoc. Competes with TuringBio for the same Korean/global consumer mental health spend via app-based subscription therapy, though without the prescription DTx regulatory layer.
• Pear Therapeutics (legacy): Was the leading US prescription DTx company (reSET, reSET-O, Somryst) before its 2023 bankruptcy and asset sale. The closest historical analog to TuringBio's DepRx regulatory and commercial pathway and a cautionary precedent for the category's economics.

Direct peers

• Akili Interactive: FDA-authorized prescription digital therapeutic company (EndeavorRx for ADHD). Comparable to TuringBio's DepRx in the prescription SaMD regulatory model, clinical-trial-driven commercialization and DTx-as-third-drug positioning.
• Woebot Health: US-based AI chatbot for mental health support, offering conversational CBT-style interventions for depression and anxiety. Closest direct comparable to TuringBio's WeeDool chatbot and DepRx digital therapeutic in target condition, modality and AI-driven approach.
• Wysa: AI chatbot for mental wellness with both consumer and enterprise/B2B distribution (employers, health plans). Comparable to TuringBio across direct-to-consumer mental health app, institutional EAP motion and chatbot-led behavioral therapy delivery.
• Big Health: Prescription and non-prescription digital therapeutics for insomnia and anxiety (Sleepio, Daylight). Directly comparable to TuringBio in the prescription digital therapeutic regulatory pathway, behavioral activation-inspired protocols, and employer/payer distribution model.

Emerging players

• Mindstrong (legacy): Was a US digital mental health company using smartphone-based digital biomarkers and AI to detect and monitor mental health conditions. Closely analogous to TuringBio's multimodal biomarker-tracking approach combining passive smartphone data with ML-based mental health assessment.
• Limbic: UK-based AI mental health platform used by the NHS for self-referral into talking therapies. Comparable to TuringBio in using AI to triage and personalize mental health treatment pathways, though focused on therapy service routing rather than prescription DTx.

Regional players

• Mind Cafe (마인드카페): Korean mental health platform providing online counseling and therapy services. Comparable regional peer to TuringBio's consumer mental health offerings, competing for the same Korean user base with live therapist delivery rather than DTx or AI chatbot models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TURINGBIO